Could this pharma stock help you become an ISA millionaire?

Roland Head considers two potential ISA buys ahead of this year’s April deadline.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in long-term dividend growth stocks within an ISA can be a great way to build wealth. You don’t have to pay capital gains tax if you sell and you can also receive dividends free of income tax.

Today I’m looking at two potential dividend growth buys. Can either of these stocks help you retire rich?

A growth market

The ageing populations of most developed countries should be good news for ConvaTec Group (LSE: CTEC), which produces a range of disposable products needed by patients with chronic conditions such as incontinence and stomas.

The group’s focus is on products which require regular repeat purchases, and where demand is expected to grow. ConvaTec’s share price initially performed strongly after its flotation in 2016, but the stock fell sharply in October last year after it warned that sales would fall below expectations due to supply disruptions.

A buying opportunity?

This fall could be a buying opportunity. The group’s recent results showed a fairly stable performance in 2017. And although supply problems are expected to impact sales during the first half of the year, organic sales are still expected to rise by 2.5% to 3% in 2018.

Analysts expect adjusted earnings to rise by 12.5% to 18 cents per share in 2018, putting the stock on a forecast P/E of 15.3. The dividend is expected to climb 20% to 6.8 cents per share, giving a prospective yield of 2.5%.

ConvaTec’s net debt remains a little too high in my view, at $1.5bn or 3 times EBITDA. But cash generation is generally good, which should help with debt reduction. If you buy into this company’s structural growth story, the current share price could be a decent entry point.

Specialist services

Cambian Group (LSE: CMBN) provides a range of specialist services to support children with behavioural problems and learning difficulties. Its share price slipped 4% lower today after the group reported a pre-tax loss of £9m for 2017.

This loss was the result of £11.2m of exceptional costs incurred last year, as the company repositions itself to focus on higher severity services, which are presumably more profitable.  

Stripping out these one-off costs gives an adjusted pre-tax profit of £2.2m for 2017, compared to a loss of £0.4m for 2016. The group’s after-tax adjusted earnings rose by 50% to 3.6p last year.

Cash returns

Cambian sold its Adult Services division at the end of 2016. Much of the cash from this sale was used to repay debt. Most of the remaining cash has now been returned to shareholders, who received a special dividend of £50m (27.1p per share) in 2017. A further £15m (8.2p per share) was returned to shareholders in February.

I’m pleased that management is showing discipline and returning surplus cash to shareholders. However, it does leave me wondering whether the company’s expansion opportunities may be limited.

My view

Chief executive Saleem Asaria says that 2018 will be “a year of consolidation” that’s needed before the company can return to growth. City analysts expect the group’s adjusted earnings to rise by 80% to 6.3p per share this year, and are forecasting an ordinary dividend of 2.9p.

These figures put the stock on a forecast P/E of 32 with a prospective yield of 1.4%. Given the uncertainty over future growth, the stock looks too expensive to me. I’d like to know more before considering an investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Road trip. Father and son travelling together by car
Investing Articles

A 10% dividend yield? There could be significant potential here to earn a second income

Mark Hartley delves into the finances and performance of one of the top-earning dividend stocks in his second income portfolio.

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Charlie Munger recommended shares in this growth company back in 2022. Here’s what’s happened since

One of Charlie Munger’s key insights is that a high P/E ratio shouldn’t put investors off buying shares if the…

Read more »

Investing Articles

What might 2025 have in store for the Aviva share price? Let’s ask the experts

After a rocky five years, the Aviva share price has inched up in 2024. And City forecasters reckon we could…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Trading around an 11-year high, is Tesco’s share price still significantly undervalued?

Although Tesco’s share price has risen a lot in the past few years, it could still have significant value left…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£11,000 in savings? Investors could consider targeting £5,979 a year of passive income with this FTSE 250 high-yield gem!

This FTSE 250 firm currently delivers a yield of more than double the index’s average, which could generate very sizeable…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

Does a 9.7% yield and a P/E under 10 make the Legal & General share price a no-brainer?

With a very high dividend yield and a falling P/E forecast, could the Legal & General share price really be…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

This growth stock is up 2,564% over 6 months! Is this FOMO?

This growth stock has experienced an incredible appreciation in its share price. It’s not a meme stock, but investors might…

Read more »

Investing Articles

This bank’s dividend yield will grow to 6.9% in 2026! And analysts say its undervalued

Analysts say this FTSE 100 stock’s dividend yield will continue to rise over the medium term. With the stock also…

Read more »